This document summarizes Michelle Boudreau's presentation at the Pharmacare 2020 Conference in Vancouver on February 26-27, 2013. The presentation outlined the policy objectives of regulating drug prices in Canada to ensure they are not excessive while recognizing pharmaceutical innovation. It described how the Patented Medicine Prices Review Board conducts price tests at drug introduction and over time, referencing international drug prices. The presentation concluded that balancing innovation and affordable access is an ongoing challenge given the dynamic pharmaceutical market.
- Tenet Healthcare Corporation reported a 1.0% increase in same-hospital admissions for Q1 2008 compared to Q1 2007. Adjusted EBITDA was $239 million for Q1 2008.
- Key strategies of physician relations programs, cost containment initiatives, and pricing enhancements are proving effective in driving volume and EBITDA growth. Volume growth has been positive for two consecutive quarters.
- The outlook for 2008 was revised with pricing strength expected to offset slower outpatient volume growth. Adjusted EBITDA is forecast to remain between $775-850 million.
- Adjusted EBITDA was R$558.9 million in 3Q07, 15.2% lower than 3Q06. Net profit was R$197.6 million, R$150.3 million higher than 3Q06.
- Average tariff decreased by 8.43% in 3Q07 due to tariff reset. Dividends of R$487.8 million were paid for 1H07 earnings.
- A R$600 million debenture issue was made in October to repay an earlier debenture issue. A voluntary dismissal program was also announced.
Trevor Fetter, President and CEO of Tenet Healthcare, discusses Tenet's strategy for progress and growth. He outlines that Tenet's culture and values are driving measurable improvements in operations, performance, and innovation. Key points include that same hospital adjusted EBITDA and margins have been expanding, volume trends are favorable, pricing growth has been strong, and they have effectively contained cost growth. Fetter also discusses strategic initiatives proving effective in quality, targeted growth, physician relationships, and capital investment. He believes Tenet has reached an "inflection point" in its turnaround over the past 12-18 months.
1 q07 financial and operating results presentationEquatorial
The document provides financial and operating results for the first quarter of 2007 for an unnamed company.
1) Net revenues increased 13.6% to R$195.1 million due to an 8.3% increase in energy sales volume and a tariff increase. EBITDA grew 13.8% to R$77 million with an EBITDA margin of 39.5%.
2) Energy sales grew 8.3% while customer base increased 7.2% compared to the prior year. Residential and industrial energy consumption grew 9.8% and 10.7% respectively.
3) Manageable costs and expenses were down 5.3% year-over-year as a percentage of
http://www.sca.com/Q32011en SCA’s interim report for the period 1 January – 30 September 2011 has been published. Operating profit , excl. restructuring costs, decreased by 5% (decreased by 1% excl. exchange rate effects) to SEK 6,697m. Net sales decreased by 1% (increased by 6% excl. exchange rate effects and divestments) to SEK 79 001m. Earnings per share rose 2% (7% excl. exchange rate effects) to SEK 5.66.
http://www.sca.com/ir
http://www.facebook.com/SCA
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
Wessanen agm 16 april 2013 presentationKlaus Arntz
Royal Wessanen nv held its Annual General Meeting of Shareholders on April 16, 2013 to discuss the company's performance in 2012 and strategic plans. [1] The company focused its portfolio on organic food between 2009 and 2012, selling off non-core brands and categories. [2] In 2012, Wessanen reported revenue of €710.8 million but an operating loss of €45.8 million due to impairment charges. [3] The company launched a transformation program called "Wessanen 2015" to make the business more focused, efficient and profitable.
The document summarizes key deal terms from middle-market mergers and acquisitions where Houlihan Lokey served as the financial advisor. It analyzes purchase agreement terms such as indemnification provisions, representations and warranties. The majority of deals involved strategic buyers acquiring stock for all cash. Earn-outs were included in 18% of deals while rollovers were included in 20% of deals. Valuation multiples like EV/EBITDA increased in 2010 from prior years.
- Tenet Healthcare Corporation reported a 1.0% increase in same-hospital admissions for Q1 2008 compared to Q1 2007. Adjusted EBITDA was $239 million for Q1 2008.
- Key strategies of physician relations programs, cost containment initiatives, and pricing enhancements are proving effective in driving volume and EBITDA growth. Volume growth has been positive for two consecutive quarters.
- The outlook for 2008 was revised with pricing strength expected to offset slower outpatient volume growth. Adjusted EBITDA is forecast to remain between $775-850 million.
- Adjusted EBITDA was R$558.9 million in 3Q07, 15.2% lower than 3Q06. Net profit was R$197.6 million, R$150.3 million higher than 3Q06.
- Average tariff decreased by 8.43% in 3Q07 due to tariff reset. Dividends of R$487.8 million were paid for 1H07 earnings.
- A R$600 million debenture issue was made in October to repay an earlier debenture issue. A voluntary dismissal program was also announced.
Trevor Fetter, President and CEO of Tenet Healthcare, discusses Tenet's strategy for progress and growth. He outlines that Tenet's culture and values are driving measurable improvements in operations, performance, and innovation. Key points include that same hospital adjusted EBITDA and margins have been expanding, volume trends are favorable, pricing growth has been strong, and they have effectively contained cost growth. Fetter also discusses strategic initiatives proving effective in quality, targeted growth, physician relationships, and capital investment. He believes Tenet has reached an "inflection point" in its turnaround over the past 12-18 months.
1 q07 financial and operating results presentationEquatorial
The document provides financial and operating results for the first quarter of 2007 for an unnamed company.
1) Net revenues increased 13.6% to R$195.1 million due to an 8.3% increase in energy sales volume and a tariff increase. EBITDA grew 13.8% to R$77 million with an EBITDA margin of 39.5%.
2) Energy sales grew 8.3% while customer base increased 7.2% compared to the prior year. Residential and industrial energy consumption grew 9.8% and 10.7% respectively.
3) Manageable costs and expenses were down 5.3% year-over-year as a percentage of
http://www.sca.com/Q32011en SCA’s interim report for the period 1 January – 30 September 2011 has been published. Operating profit , excl. restructuring costs, decreased by 5% (decreased by 1% excl. exchange rate effects) to SEK 6,697m. Net sales decreased by 1% (increased by 6% excl. exchange rate effects and divestments) to SEK 79 001m. Earnings per share rose 2% (7% excl. exchange rate effects) to SEK 5.66.
http://www.sca.com/ir
http://www.facebook.com/SCA
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
Wessanen agm 16 april 2013 presentationKlaus Arntz
Royal Wessanen nv held its Annual General Meeting of Shareholders on April 16, 2013 to discuss the company's performance in 2012 and strategic plans. [1] The company focused its portfolio on organic food between 2009 and 2012, selling off non-core brands and categories. [2] In 2012, Wessanen reported revenue of €710.8 million but an operating loss of €45.8 million due to impairment charges. [3] The company launched a transformation program called "Wessanen 2015" to make the business more focused, efficient and profitable.
The document summarizes key deal terms from middle-market mergers and acquisitions where Houlihan Lokey served as the financial advisor. It analyzes purchase agreement terms such as indemnification provisions, representations and warranties. The majority of deals involved strategic buyers acquiring stock for all cash. Earn-outs were included in 18% of deals while rollovers were included in 20% of deals. Valuation multiples like EV/EBITDA increased in 2010 from prior years.
The Tipping Point: Data Center 2.0 - Kevin Malik CIO of IO and GM of IO LabsIO
Addressing each layer of the IT stack, Kevin walks attendees through the math and why it simply doesn’t add up in favor of traditional data centers. Trends in population, proliferation of applications, data storage and management, and energy consumption mean that the data center MUST evolve to avoid systemic disaster economically and environmentally. Processing, storage, and networking capabilities are progressing at breakneck speeds, and the data center must keep pace. The construction-based approach to data centers takes too long, costs too much, is inelastic, and insecure. There is a better way.
Anna Reid, Canadian Medical Association - Visions for PharmacarePharmacare 2020
Dr. Anna Reid, president of the Canadian Medical Association, presented her vision for universal pharmacare coverage in Canada at the Pharmacare 2020 conference. She argued that nearly 1 in 10 Canadians cannot afford their prescription drugs due to gaps in both public and private coverage plans. While groups like the CMA have advocated since 2006 for a national strategy to address this issue, no significant progress has been made. Dr. Reid called for stakeholders to work together to identify the uninsured, build on existing coverage programs, consider all solutions flexibly, and ensure equitable access across provinces with federal leadership.
Steve Morgan - What Could Work? Will We Ever Get There?Pharmacare 2020
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help boost feelings of calmness, happiness and focus.
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in CanadaPharmacare 2020
This document discusses current challenges with prescription drug plans in Canada from an employer's perspective. It provides an overview of Magna International, a global automotive supplier, and compares their U.S. and Canadian Rx plans. The Canadian plan has higher generic and brand drug prices than the U.S. plan. It also discusses limitations of Canadian pharmacy benefit managers and considers options for making future Rx plans more cost effective and clinically focused.
This document lists 4 items: José Parlá, Naoya Hatakeyama, Water, and Reflections. It appears to be a list of topics or subjects but provides no other context or details about the items listed.
Proyectos de equipamiento para Educación
Laboratorio de idiomas, Laboratorio de ciencias, Biblioteca digital, Aula multimedia, Talleres para ingenierías
This document lists the names of 13 photographers known for their documentary and street photography work. Some of the photographers mentioned include Diane Arbus, Walker Evans, Robert Frank, Bruce Davidson, and Eve Arnold. Overall, the document provides a list of influential documentary and street photographers without any additional context.
Michael McBane, Canadian Health Coalition - Visions for PharmacarePharmacare 2020
Pharmacare would provide more affordable and universal access to prescription drugs for Canadians. It would save $10.7 billion by establishing a national formulary to negotiate competitive drug prices in bulk, only paying for drugs that are safe and cost-effective, and improving prescribing practices. The current system lacks affordable access for many Canadians and has rising drug costs above international averages that contribute to serious health issues.
REFRIGERACION-CLIMATIZACION
Camara fria positiva
Estudio de un climatizador split inverso
Banco ilustrativo para el manejo de fluidos frigoricos
Estudio de la produccion de agua helada por condensacion usando aire
Estudio de ciclo frigorifico
Central de acondicionamiento de aire
Plataforma central de acondicionamiento de aire
FLUIDOS TRANSFER TERMICOS
Estudio de 2 intercambiadores termicos
Estudio de dos bombas centrifugas
Equipo de hidrostatico de propiedades de fluidos
Estudio de la ecuación de Bernoulli
Estudio de un ventilador axial
Estudio de las bombas y perdidas de carga
Estudio de las perdidas de carga
Equipo de turbina pelton
Torre de enfriamiento
ENERGIAS RENOVABLES
Banco de calentamiento solar termico
PROCESO INDUSTRIAL
Produccion y distribucion de vapor
Plataforma de turbina de vapor 1kw
Sistema automatico de dosificacion y llenado
INGENIERÍA ELÉCTRICA, ELECTRÓNICA, CONTROL
Máquinas eléctricas y variadores
Electrónica de potencia
Sistemas electrónicos
Automatismos
Control
INGENIERÍA MECATRÓNICA y MECÁNICA
Máquina de corte por chorro de agua
Resistencia de materiales y estructuras
Ensayos sísmicos
Ingeniería mecánica
Bancos electro-neumáticos y neumáticos
INGENIERÍA MANTENIMIENTO y PILOTAJE DE PRODUCCIÓN
Línea de fabricación y acondicionamiento
Célula robotizada 6 ejes
Banco hidráulico aeronáutico
Mantenimiento de bombas
Mantenimiento de válvulas
ENERGÍAS RENOVABLES e INGENIERÍA TÉRMICA
Solar fotovoltáico (sitio aislado/conectado a la red)
Eólica (sitio aislado/conectado a la red)
Solar térmico
Bomba de calor
Aire acondicionado
Ventilación / Tratamiento del aire
El documento presenta al Grupo EDUTECNO BIOenergy, el cual ofrece proyectos y soluciones integrales en educación, energía, medio ambiente e innovación. El grupo trabaja en conjunto para proporcionar proyectos llave en mano en áreas como residuos, alumbrado público, contenedores, rehabilitación de pozos, seguridad e innovación/investigación. Proporciona información de contacto de la compañía en la Ciudad de México y Morelia, Michoacán.
PROCESOS QUÍMICOS Y OPERACIONES UNITARIAS
Absorción, Adsorción, Cristalización, Destilación, Evaporación, Extracción líquido - líquido, Filtración, Reacción - Síntesis, Mini pilotos, Pilotos +
FLUIDOS - FLUIDIZACIÓN
INTERCAMBIO DE CALOR
INSTRUMENTACIÓN Y CONTROL
TRATAMIENTO DE AGUAS
Saneamiento
Potabilización
Acabado
Tratamiento de desechos industriales
BIO INDUSTRIA
Planta de bioetanol
1) Avery Dennison presented preliminary financial results for the first half of 2006, showing earnings per share up 14% due to improved margins.
2) Key priorities include maintaining pricing discipline, achieving $85-100 million in annual savings from restructuring, and accelerating organic sales growth to a target range of 4-6% over the medium term.
3) Emerging markets are seen as a major growth driver, expected to increase their contribution to overall growth and profitability significantly by 2010.
This document provides information about Johnson & Johnson, including:
1. A group of 5 students proposed the slogan "Caring for you from the beginning, to the very end!" for Johnson & Johnson.
2. Johnson & Johnson was founded in 1886 and has since pioneered many health and consumer products and expanded globally through acquisitions.
3. The document outlines Johnson & Johnson's vision, mission, objectives, organizational structure, market analysis, and SWOT analysis. It recommends strategies for the company to increase R&D and highlight the value of its products to increase market share.
The document summarizes CPG industry performance in 2012, finding that unit sales were largely flat while dollar sales growth was driven by inflation. Channel performance varied, with convenience outperforming other channels. Categories related to health, beauty and home cooking saw stronger growth. Looking ahead, the recovery faces challenges while private label growth trends differ across channels and departments.
Colgate Palmolive developed a new toothbrush called Colgate Precision and the product manager must recommend a marketing strategy. There is a conflict over the advertising budget between Colgate Precision and Colgate Plus. The product manager proposes progressively increasing the total budget and allocating 25% more to Precision each year. Analyzing pricing and sales projections, niche positioning earns $1.79 million in profit Year 1 and $19.96 million Year 2, showing increased volume leads to higher profits.
Procter & Gamble is the world's largest consumer goods company, known for brands like Always, Braun, Bounty, Charmin, Crest, Downy, Febreze, Gillette, Olay, Pampers, Pantene, Tide, and Wella. The document analyzes P&G's business in 2011 through external and internal audits, strategic frameworks like BCG matrix and IE matrix, and recommends strategies like increasing investments in R&D, targeting male consumers through celebrity endorsements, and focusing marketing of established brands on their brand recognition. The analyses aim to help P&G accelerate growth, especially in emerging markets
This study analyzed the relationships between pharmacy benefit design, generic drug dispensing rates, and mail service utilization using data from 367 employers and 27 health plans covering over 11 million members from 2005-2006. The researchers found that both brand and generic member out-of-pocket costs impacted utilization in nonlinear ways. Certain benefit design elements like deductibles, dispense-as-written penalties, and maximum allowable benefits were associated with higher generic dispensing and mail service utilization rates. The results suggest that prior studies on the effects of cost-sharing on drug utilization may have been biased by omitting other benefit design factors, mail fulfillment options, and trends in generic and brand drug use over time. Limitations include potential endogeneity of
Pharmacy Benefit Design, Generic Dispensing, and Mail Service UtilizationM. Christopher Roebuck
This study analyzed the relationships between pharmacy benefit design, generic drug dispensing rates, and mail service utilization using data from 367 employers and 27 health plans covering over 11 million members from 2005 to 2006. The researchers found that both brand and generic member out-of-pocket costs affected utilization in nonlinear ways. Certain benefit design elements like deductibles, dispense-as-written penalties, and maximum allowable benefits were linked to higher generic dispensing and mail service utilization. The results suggest that prior studies may have oversimplified the impact of cost-sharing by ignoring other benefit design factors, mail fulfillment options, and trends in generic and brand drug use over time. Limitations include potential endogeneity of benefit design variables, though
The Tipping Point: Data Center 2.0 - Kevin Malik CIO of IO and GM of IO LabsIO
Addressing each layer of the IT stack, Kevin walks attendees through the math and why it simply doesn’t add up in favor of traditional data centers. Trends in population, proliferation of applications, data storage and management, and energy consumption mean that the data center MUST evolve to avoid systemic disaster economically and environmentally. Processing, storage, and networking capabilities are progressing at breakneck speeds, and the data center must keep pace. The construction-based approach to data centers takes too long, costs too much, is inelastic, and insecure. There is a better way.
Anna Reid, Canadian Medical Association - Visions for PharmacarePharmacare 2020
Dr. Anna Reid, president of the Canadian Medical Association, presented her vision for universal pharmacare coverage in Canada at the Pharmacare 2020 conference. She argued that nearly 1 in 10 Canadians cannot afford their prescription drugs due to gaps in both public and private coverage plans. While groups like the CMA have advocated since 2006 for a national strategy to address this issue, no significant progress has been made. Dr. Reid called for stakeholders to work together to identify the uninsured, build on existing coverage programs, consider all solutions flexibly, and ensure equitable access across provinces with federal leadership.
Steve Morgan - What Could Work? Will We Ever Get There?Pharmacare 2020
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help boost feelings of calmness, happiness and focus.
Arthur Fabbro - Role of Private Insurance for Prescription Drugs in CanadaPharmacare 2020
This document discusses current challenges with prescription drug plans in Canada from an employer's perspective. It provides an overview of Magna International, a global automotive supplier, and compares their U.S. and Canadian Rx plans. The Canadian plan has higher generic and brand drug prices than the U.S. plan. It also discusses limitations of Canadian pharmacy benefit managers and considers options for making future Rx plans more cost effective and clinically focused.
This document lists 4 items: José Parlá, Naoya Hatakeyama, Water, and Reflections. It appears to be a list of topics or subjects but provides no other context or details about the items listed.
Proyectos de equipamiento para Educación
Laboratorio de idiomas, Laboratorio de ciencias, Biblioteca digital, Aula multimedia, Talleres para ingenierías
This document lists the names of 13 photographers known for their documentary and street photography work. Some of the photographers mentioned include Diane Arbus, Walker Evans, Robert Frank, Bruce Davidson, and Eve Arnold. Overall, the document provides a list of influential documentary and street photographers without any additional context.
Michael McBane, Canadian Health Coalition - Visions for PharmacarePharmacare 2020
Pharmacare would provide more affordable and universal access to prescription drugs for Canadians. It would save $10.7 billion by establishing a national formulary to negotiate competitive drug prices in bulk, only paying for drugs that are safe and cost-effective, and improving prescribing practices. The current system lacks affordable access for many Canadians and has rising drug costs above international averages that contribute to serious health issues.
REFRIGERACION-CLIMATIZACION
Camara fria positiva
Estudio de un climatizador split inverso
Banco ilustrativo para el manejo de fluidos frigoricos
Estudio de la produccion de agua helada por condensacion usando aire
Estudio de ciclo frigorifico
Central de acondicionamiento de aire
Plataforma central de acondicionamiento de aire
FLUIDOS TRANSFER TERMICOS
Estudio de 2 intercambiadores termicos
Estudio de dos bombas centrifugas
Equipo de hidrostatico de propiedades de fluidos
Estudio de la ecuación de Bernoulli
Estudio de un ventilador axial
Estudio de las bombas y perdidas de carga
Estudio de las perdidas de carga
Equipo de turbina pelton
Torre de enfriamiento
ENERGIAS RENOVABLES
Banco de calentamiento solar termico
PROCESO INDUSTRIAL
Produccion y distribucion de vapor
Plataforma de turbina de vapor 1kw
Sistema automatico de dosificacion y llenado
INGENIERÍA ELÉCTRICA, ELECTRÓNICA, CONTROL
Máquinas eléctricas y variadores
Electrónica de potencia
Sistemas electrónicos
Automatismos
Control
INGENIERÍA MECATRÓNICA y MECÁNICA
Máquina de corte por chorro de agua
Resistencia de materiales y estructuras
Ensayos sísmicos
Ingeniería mecánica
Bancos electro-neumáticos y neumáticos
INGENIERÍA MANTENIMIENTO y PILOTAJE DE PRODUCCIÓN
Línea de fabricación y acondicionamiento
Célula robotizada 6 ejes
Banco hidráulico aeronáutico
Mantenimiento de bombas
Mantenimiento de válvulas
ENERGÍAS RENOVABLES e INGENIERÍA TÉRMICA
Solar fotovoltáico (sitio aislado/conectado a la red)
Eólica (sitio aislado/conectado a la red)
Solar térmico
Bomba de calor
Aire acondicionado
Ventilación / Tratamiento del aire
El documento presenta al Grupo EDUTECNO BIOenergy, el cual ofrece proyectos y soluciones integrales en educación, energía, medio ambiente e innovación. El grupo trabaja en conjunto para proporcionar proyectos llave en mano en áreas como residuos, alumbrado público, contenedores, rehabilitación de pozos, seguridad e innovación/investigación. Proporciona información de contacto de la compañía en la Ciudad de México y Morelia, Michoacán.
PROCESOS QUÍMICOS Y OPERACIONES UNITARIAS
Absorción, Adsorción, Cristalización, Destilación, Evaporación, Extracción líquido - líquido, Filtración, Reacción - Síntesis, Mini pilotos, Pilotos +
FLUIDOS - FLUIDIZACIÓN
INTERCAMBIO DE CALOR
INSTRUMENTACIÓN Y CONTROL
TRATAMIENTO DE AGUAS
Saneamiento
Potabilización
Acabado
Tratamiento de desechos industriales
BIO INDUSTRIA
Planta de bioetanol
1) Avery Dennison presented preliminary financial results for the first half of 2006, showing earnings per share up 14% due to improved margins.
2) Key priorities include maintaining pricing discipline, achieving $85-100 million in annual savings from restructuring, and accelerating organic sales growth to a target range of 4-6% over the medium term.
3) Emerging markets are seen as a major growth driver, expected to increase their contribution to overall growth and profitability significantly by 2010.
This document provides information about Johnson & Johnson, including:
1. A group of 5 students proposed the slogan "Caring for you from the beginning, to the very end!" for Johnson & Johnson.
2. Johnson & Johnson was founded in 1886 and has since pioneered many health and consumer products and expanded globally through acquisitions.
3. The document outlines Johnson & Johnson's vision, mission, objectives, organizational structure, market analysis, and SWOT analysis. It recommends strategies for the company to increase R&D and highlight the value of its products to increase market share.
The document summarizes CPG industry performance in 2012, finding that unit sales were largely flat while dollar sales growth was driven by inflation. Channel performance varied, with convenience outperforming other channels. Categories related to health, beauty and home cooking saw stronger growth. Looking ahead, the recovery faces challenges while private label growth trends differ across channels and departments.
Colgate Palmolive developed a new toothbrush called Colgate Precision and the product manager must recommend a marketing strategy. There is a conflict over the advertising budget between Colgate Precision and Colgate Plus. The product manager proposes progressively increasing the total budget and allocating 25% more to Precision each year. Analyzing pricing and sales projections, niche positioning earns $1.79 million in profit Year 1 and $19.96 million Year 2, showing increased volume leads to higher profits.
Procter & Gamble is the world's largest consumer goods company, known for brands like Always, Braun, Bounty, Charmin, Crest, Downy, Febreze, Gillette, Olay, Pampers, Pantene, Tide, and Wella. The document analyzes P&G's business in 2011 through external and internal audits, strategic frameworks like BCG matrix and IE matrix, and recommends strategies like increasing investments in R&D, targeting male consumers through celebrity endorsements, and focusing marketing of established brands on their brand recognition. The analyses aim to help P&G accelerate growth, especially in emerging markets
This study analyzed the relationships between pharmacy benefit design, generic drug dispensing rates, and mail service utilization using data from 367 employers and 27 health plans covering over 11 million members from 2005-2006. The researchers found that both brand and generic member out-of-pocket costs impacted utilization in nonlinear ways. Certain benefit design elements like deductibles, dispense-as-written penalties, and maximum allowable benefits were associated with higher generic dispensing and mail service utilization rates. The results suggest that prior studies on the effects of cost-sharing on drug utilization may have been biased by omitting other benefit design factors, mail fulfillment options, and trends in generic and brand drug use over time. Limitations include potential endogeneity of
Pharmacy Benefit Design, Generic Dispensing, and Mail Service UtilizationM. Christopher Roebuck
This study analyzed the relationships between pharmacy benefit design, generic drug dispensing rates, and mail service utilization using data from 367 employers and 27 health plans covering over 11 million members from 2005 to 2006. The researchers found that both brand and generic member out-of-pocket costs affected utilization in nonlinear ways. Certain benefit design elements like deductibles, dispense-as-written penalties, and maximum allowable benefits were linked to higher generic dispensing and mail service utilization. The results suggest that prior studies may have oversimplified the impact of cost-sharing by ignoring other benefit design factors, mail fulfillment options, and trends in generic and brand drug use over time. Limitations include potential endogeneity of benefit design variables, though
Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS MarketAMMindpower
The report titled “Global Healthcare IT Market Outlook to 2016 – Evolving mHealth and PACS Market” provides a comprehensive analysis on the total number of Global healthcare IT market size, segmentation of healthcare IT market, EMR segment, PACS market, Telemedicine market, telemonitoring market and mHealth market. The report provides the competitive landscape of global healthcare IT market, global EMR market and global PACS market. The report also discusses major trends and developments in the global mHealth and Healthcare IT market, company profile players, and the cause and effect relationship between industry factors and global healthcare IT market prospects. The future projections included in the report provide an insight on the prospects in the Global healthcare IT market, EMR market, mHealth market, telemedicine market, telemonitoring market and PACS market.
For more information on the industry research report please refer to the below mentioned link:
http://www.ammindpower.com/report.php?A=302&T=D&S=91
The document provides a summary of the company's financial results for the second quarter of 2006. Key points include:
- Earnings per share increased 8% driven by productivity improvements that expanded operating margins.
- Net sales were even with the prior year due to divestitures and currency impacts, but organic sales grew 2%.
- Margins improved due to productivity gains, though this was partially offset by transition costs and inflation.
- The company is realizing annual savings from restructuring of $85-100 million and raising its cost reduction target.
Evolving Operational Business Model in Pharmaceutical IndustrySurya Chitra,PhD MBA
The pharmaceutical industry is changing its business and operational models due to various pressures. The current model of vertical integration from research to pharmacy is shifting to a more fragmented model. Key drivers include rising costs, price pressures, increased regulation, and patent expirations. The industry must address these issues to sustain growth and profits. Alternative business strategies are needed due to instability in the current blockbuster drug model, which relies on a few highly profitable drugs to offset research and development costs.
Point of care testing market and forecast to 2016 global analysisRenub Research
Renub Research (http://www.renub.com/report/point-of-care-testing-market-and-forecast-to-2016-global-analysis-88) has announced the addition of the "Point of Care Testing Market and Forecast to 2016: Global Analysis" report to its offering
Point of Care Testing Market and Forecast to 2016: Global Analysis - Market Overview
The concept of Point of Care Testing (POCT), also known as bedside, near-patient testing and decentralized testing, relates to tests that are conducted by clinical operators at the site of patient care where immediate medical action is taken on the results. The fact that point of care (POCT) represents a departure from conventional laboratory medicine has created new opportunities in the field of diagnostics industry. Technical advancements over recent years have helped point of care testing (POCT) to grow with double digit CAGR from 2009 to 2011 and evolve into a vital diagnostic tool. It is predicted that point of care testing market will be approximately US$ 25 Billion by 2016.
Blood glucose test controls a lion’s market share of around 70% for the year 2011 and it is expected to continue its dominance till 2016. Rest of all the others point of care tests market share covered in this report are in single digit. Infectious disease testing market is expected to double by 2016 from its market of 2011. As countries are making the healthcare more and more accessible to people, the demand for various point of care testing is keep on rising. The point of care testing market has become an established sector worldwide and will continue to provide vital contribution in in-vitro diagnostics industry.
This 83 page report contains 26 Figures and 12 Tables provides a comprehensive analysis of the emerging point of care tests market segments, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Renub Research report entitled “Point of Care Testing Market and Forecast to 2016: Global Analysis” report also provides market landscape and market share information in the point of care testing market. The report brings together major merger & acquisition, distribution agreement, licensing deals information in point of care testing market. The report also entails major drivers and challenges of point of care testing market.
10 Point of Care Test Segments Covered in this Report
Blood Glucose Testing, Cardiac Marker Testing, Lipid Panel/Cholesterol Testing, Blood Coagulation Testing, Infectious Disease Testing, Urinalysis Testing, Drug of Abuse Testing, Fecal Occult Blood Testing, Pregnancy & Fertility Testing and Tumor Marker Testing
Opportunities And Threats Of Entering New Markets New Geos Powerpoint Present...SlideTeam
Introducing our Opportunities And Threats Of Entering New Markets New Geos PowerPoint Presentation Slides to help you create a successful business expansion plan step-by-step. Identify the available geographic strategic options best-suited to widen your market base by taking the help of these entry strategy PPT slides. Use this swot analysis PPT template to elaborate on the plan of action for business growth, like expansion in successful existing geos, entering new geos, and dropping unsuccessful geos. Employ these content-specific market entry PPT layouts to carry out effective market research for your business. Highlight the process as well as the importance of value proposition analysis by taking the aid of these commercialization strategy PPT designs. Take advantage of our matrix template for this geographic expansion strategy PPT presentation to score each potential geo on the criteria of market opportunities like growth potential, competition level, investment, risk, and legal aspects. Download this global marketing effort PPT deck and create a roadmap for successful business expansion in the global market. https://bit.ly/3cJ7cx9
The document summarizes factors that could offset negative impacts on the US market from political developments in Europe. It notes that forward earnings estimates for US companies are increasing for the first time in three quarters. Consumer stimulus is also expected from lower oil prices over the northern summer. Spending on durable goods like vehicles and housing is stronger than last year. The author believes these positive factors will allow the US market to advance over the next few months despite troubles in Europe.
Nordion reported its financial results for the fourth quarter of fiscal year 2012. Total revenue was $74.7 million, with a GAAP net loss of $43.5 million. However, adjusted net income was $21.4 million, up 14% from the fourth quarter of 2011. Targeted Therapies revenue grew 10% to $32.5 million in the quarter. Sterilization Technologies revenue was $32.3 million. Medical Isotopes revenue declined slightly to $30.3 million. For fiscal year 2013, Nordion expects revenue growth in Targeted Therapies and stable revenue in Sterilization Technologies, but a 20% decline in Medical Isotopes revenue.
Norway Patient Monitoring Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The document is a report from Global Markets Direct titled "Norway Patient Monitoring Investment Opportunities, Analysis and Forecasts to 2018". It provides market data and analysis for various patient monitoring market categories in Norway from 2004-2018. The 144-page report was published in October 2012 and costs $2,500 for a single-user license. It contains market sizing data, forecasts, company shares, and profiles of key market participants in the Norway patient monitoring market.
This presentation provides an overview of the company. Key points include:
- The company is a fast growing cancer genetics lab serving oncologists, pathologists, and hospitals.
- Recent acquisition of Clarient is expected to more than double revenue and more than triple adjusted EBITDA in 2016.
- The company has a large addressable market of $5 billion that is growing due to cancer prevalence increasing with an aging population and more cancer tests through precision medicine.
- Recent financial performance shows year-over-year revenue growth of 142% and adjusted EBITDA growth of 224% for the first three quarters of 2016, which includes the effects of the Clarient acquisition.
The document discusses the global diabetes care market and insulin market. It notes that diabetes is a growing global epidemic driven by lifestyle changes and demographics. The insulin market has seen sustained double-digit growth due to factors like increasing diagnosis and treatment rates, intensifying insulin regimens, and device penetration. Insulin consumption is expected to continue increasing significantly in coming decades. Modern insulin now constitutes over 80% of the insulin market by value due to upgrades in treatment. Characteristics of the insulin industry include a chronic disease leading to long patient-drug relationships and brand loyalty.
Canadian Institute Conference - Arvind Mani's Presentation - Final - April 1 ...Arvind Mani
This document summarizes global trends in drug pricing, reimbursement, and market access. It provides data on pharmaceutical R&D spending, employment, sales, and other metrics for key global markets including the US, Europe, and Canada. It then discusses factors that impact drug pricing internationally and in Canada, such as external price referencing and currency fluctuations. Emerging trends in global cost containment like delisting treatments, off-label prescribing, and biosimilar uptake that could affect the Canadian market are also examined based on a survey of international and Canadian industry and payer perspectives.
This document summarizes a statistics project analyzing the impact of oil price fluctuations on consumer price index (CPI) in Kenya. The project used time series and linear modeling to analyze the relationship between CPI and prices of diesel and petrol. It found a strong positive correlation between CPI and oil prices. Forecasting models predicted increasing trends in CPI and oil prices over the next 6 months. The study concluded CPI and local oil prices are directly related and both showed uptrends throughout the analysis period.
Similar to Michelle Boudreau - Patented Drug Pricing and Coverage (20)
The conference was attended by approximate 200 experts representing a wide range of views on pharmaceutical policy issues: the pharmaceutical industry, public and private drug plans, government, nonprofit organizations, health professions, and academia. Over 90% of the participants at the conference said that the pharmacare system in Canada needed to be reformed.
Data presented here are from audience polling at the Pharmacare 2020 conference held on 26/27 Feb 2013 in Vancouver.
Polling was conducted electronically and was strictly voluntary and anonymous.
173 of approximately 200 delegates participated in polling (>80% participation rate). 168 delegates (>80%) answered questions about the sector in which they work. Sector-specific results are not reported for groups with 5 or fewer polling participants (e.g., private insurers and representatives of “other” sectors).
The text of some questions and answers has been edited slightly to fit presentation slides. Some percentages do not add up to 100 because of rounding.
Jordan Bateman, Canadian Taxpayers Federation - Visions for PharmacarePharmacare 2020
The document discusses issues with government-run healthcare and pharmacare programs in Canada, and proposes alternatives. It argues that [1] government programs routinely go over budget, using examples like the long gun registry and MP pensions, [2] a large portion of drug costs are already covered through private plans but governments still want to expand their role, and [3] the best approach is means-tested subsidies to encourage competitive private insurance rather than an expanded government-run program.
Three key points emerged from the document:
1) Patient advocacy groups and unions see the choice of drug as a matter between doctors and patients, and do not want employers, governments, or others interfering in drug decisions.
2) Both patient groups and unions want new drugs and devices to be publicly funded, believing they are safer and more effective, though cost is a major concern for Pharmacare plans and employers.
3) Unions and their members generally support the idea of national Pharmacare but more education is needed to help members understand and support evidence-based managed formularies being negotiated by employers.
Marc-Andre Gagnon - Pharmacare in Canada TodayPharmacare 2020
This document summarizes Canada's current situation regarding prescription drug access and costs. It notes that Canada spends $27.2 billion annually on prescription drugs, with costs increasing 10% per year on average since 1985, despite generics and patent expirations. Coverage is uneven across provinces and depends on employment rather than medical need. Private insurance administers most coverage and has higher administrative costs than public plans. The document argues for reforming the system to improve equitable access and contain rising costs through a universal public pharmacare program.
Michael Law - Generic Drug Pricing and AvailabilityPharmacare 2020
This document summarizes a study on generic drug pricing in Canada. The study found that (1) prices of generic drugs in Canada have declined significantly since 2006 but remain much higher than equivalent prices in other countries, (2) Canadians pay up to 15 times more for some generic drugs than consumers in the US, New Zealand and other countries, and (3) even Canadian generic drug companies sell some drugs for much lower prices in other countries compared to in Canada.
Mark Collison, Heart & Stroke Foundation - Visions for PharmacarePharmacare 2020
Mark Collison from the Heart and Stroke Foundation outlines their vision for a national pharmacare program in Canada. [1] The program would provide all Canadians with timely, affordable, and flexible prescription drug coverage focused on optimal health outcomes. [2] It would strive to be sustainable in the long-term while providing value for healthcare investments. [3] The primary goals of the program are to ensure equitable coverage and catastrophic coverage for all, establish reasonable access standards, involve both public and private payers, offer accommodating and autonomous patient choice among treatment options, enable best practices and self-management through system capacity, and balance affordability, accountability and sustainability for quality outcomes.
Marie-Claude Premont - Role of Private Insurance for Prescription Drugs in Ca...Pharmacare 2020
The document discusses the role of private health insurance in Quebec's public drug insurance plan. Some key points:
1) Quebec's plan provides universal drug coverage but is considered "general" rather than "universal" due to the significant role of private insurers.
2) Private health insurance is limited under a universal public plan but is important under Quebec's general plan, with markets reserved for private plans.
3) Quebec's plan has structural characteristics of a private insurance model, including risk screening, premiums, deductibles, and tax-like powers given to private insurers.
Jim Keon - Generic Drug Pricing and AvailabilityPharmacare 2020
The document discusses the value of generic drug pricing in Canada. It provides statistics showing that in 2012, generics accounted for 63% of prescriptions but only 24% of drug costs, while brand drugs were 37% of prescriptions but 76% of costs. Generics have lower average retail prices of $25 versus $74 for brands. Increased use of generics could save Canada billions according to analyses. However, some argue tendering generics carries risks like shortages or less competition.
Diane McArthur - Patented Drug Pricing and CoveragePharmacare 2020
The document discusses challenges with rising drug costs for public drug programs in Ontario. It outlines how Ontario has implemented Product Listing Agreements (PLAs) with drug companies to improve access to drugs, accountability, and value. PLAs have led to improved access to therapies but negotiating them is resource-intensive. The document also discusses collaboration through the Pan-Canadian Brand Drug Pricing Alliance to leverage collective bargaining power across provinces to lower drug costs.
The document provides an overview of the BC PharmaCare program, which is the public drug insurance program in British Columbia. It details the program's budget, beneficiaries served, and expenditures by plan type. It also discusses trends showing increasing drug costs and examines challenges around controlling expenditures. The new Assistant Deputy Minister expresses interest in initiatives around generic drug pricing, formulary management, high-cost drugs, drug shortages, supply chain complexity, integration of drug use into primary care, and ensuring affordability, sustainability, accessibility and accountability of the program.
Stephen Frank - Role of Private Insurance for Prescription Drugs in CanadaPharmacare 2020
Private insurance plays an important role in supplementing Canada's public healthcare system by covering around 14% of total healthcare spending. While private insurers have to navigate a complex system with different provincial rules, they have adopted outsourcing and active plan management strategies to reduce costs and increase efficiency. Going forward, a mixed public-private system is optimal to ensure universal coverage while leveraging the strengths of both sectors in adapting to changes and controlling expenditures.
2. Outline
________________________________________________
Policy objectives in practice
How does it really work: an imperfect alignment?
Concluding remarks
2
3. Policy Objectives in Practice - key quotes and court
pronouncements
______________________________________________
“…changes (to Bill C-22) will also ensure consumer protection by
creating a drug prices review board to monitor drug prices. . .”
The Honourable Harvie Andre made this comment upon
introducing Bill C-22 for second reading on November 20,
1986.
The protection of consumer interests was one of the “Five
Pillars” of public policy addressed by amendments to the
Patent Act creating the PMPRB.
3
4. Policy objectives in practice- key quotes and court
pronouncements
______________________________________________
“…The Board’s interpretation of its mandate under the relevant
provisions was consistent with its consumer protection purpose
and should not be disturbed.”
Supreme Court of Canada’s decision in the Celgene/Thalomid
matter, January 2011
4
5. Policy objectives in challenging and changing reality…
________________________________________________
Policy objective of the day – 25 years ago – was Canada’s drug prices
would never be the highest and would be, on average, in the “middle”
Very dynamic market with many factors at play
A national regulatory framework that sets a ceiling (“non-excessive price”)
for all consumers, all patented drugs and all payers and cash-paying
consumers
Transparency in pricing around the globe makes comparisons increasingly
challenging as a price regulator
5
6. How does it really work - price tests
________________________________________________
Blend of therapeutic improvement & international referencing
Recognize incremental pharmaceutical innovation
At introduction, price premium aligned with therapeutic improvement:
Four levels of therapeutic improvement:
1) Breakthrough – Median of International Price Comparison (MIPC)
2) Substantial Improvement – Higher of top of Therapeutic Class Comparison
(TCC) and the MIPC
3) Moderate Improvement – Higher of mid-point between top of TCC test and the
MIP, and top of TCC (primary & secondary factors apply here)
4) Slight/No Improvement – Top of TCC
After introduction, monitor Average Transaction Price (ATP)
subject to CPI based price increases and cannot be greater
than highest international price (HIP)
6
7. How does it really work - price tests
________________________________________________
Price tests are applied in accordance with therapeutic
improvement
Based on specific circumstances, price ceilings at intro
may be set differently
For example, in 2011, within the “slight or no improvement
category” (70% of new drugs)
the highest international price comparison (HIPC) test sets the
Maximum Average Potential Price (MAPP) 30% of the time because
the TCC was higher than HIPC, or a TCC could not be conducted
the TCC sets the MAPP 40% of the time
7
8. How does it really work - MAPP compared with public
price
________________________________________________
Drug Cat Intro- Intro - Pivotal MAPP Intro Publicly
MIP HIPC Test Bench available
Price price
(ATP)
Brand-X SNI 1.15 2.95 TCC 2.45 0.68 0.69
Brand-Y SNI 1.40 1.85 TCC 1.52 1.50 1.50
Generic-A SNI 0.85 1.50 TCC* 0.65 0.42 0.33
* Brand price sets the MAPP – brand price $0.65
8
9. Average Ratio of 2011 Price to Introductory Price, by
Year of Introduction
________________________________________________
1.10
1.06 1.06 1.06
1.05 1.04
1.03
1.02
1.01 1.01
1.00
1.00 0.99
0.98 0.99
Ratio
0.97
0.95 0.94
0.93
0.93
0.90
0.85
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Source: PMPRB
9
10. Concluding remarks
________________________________________________
Recognizing innovation and ensuring a non-excessive price = a delicate
balance
Very dynamic market with many factors at play
Consumer protection vis-à-vis drug pricing remains an important policy
objective
Transparency in pricing around the globe makes comparisons increasingly
challenging as a price regulator
Affordable access and sustainability is a concern shared by
consumers, regulators and payers
10
13. Market trends - Canada Compared to the World
________________________________________________
In 2005 and 2011, Canadian drug sales accounted for 2.4% and
2.6%, respectively, of the global market
Small, but significant market
13
14. Market trends - Canada Compared to the World
________________________________________________
Growth in drug sales outpacing comparator countries
14
15. Market trends - Canada Compared to the World
________________________________________________
Canadian prices comparatively higher than a number of OECD
countries
2.50
Avg Bilateral Foreign-to-Canadian Price Ratios: Top 300 selling oral solids in Canada
2.00
1.50
1.00
0.50
0.00
IMS Health Data, 2010
15
16. Market trends - Canadian Public Drug Plan* Spending on Rx
Drugs, Rates of Growth and Annual Totals, 2005/06 to 2010/11
* NPDUIS, all public drug plans, including NIHB, are included with the exception of Newfoundland; Yukon; NWT’s and Quebec. Its important to
keep in mind that there may be some provincial plans, like disease specific plans, that are not included even if the province is included. The totals
include drug cost, retail/wholesale mark-ups as well as dispensing fees.
16
17. PMPRB Price Tests - How Does it Really Work?
________________________________________________
Of the 109 New Drug Products introduced in 2011:
12% under investigation
69% were of slight or no improvement
25% of moderate improvement
5% of substantial improvement 1% breakthrough
17
18. PMPRB Price Tests - International Referencing
________________________________________________
Reference pricing at introduction and for existing drugs based on 7
comparator countries - France, Germany, Italy, Sweden, Switzerland, UK, and US
Policy changes in these countries could impact prices in Canada
Over last three years, Germany has most often been the highest
referenced price for PMPRB price tests, followed by US
Recent cost containment measures by reference countries may lead to lower prices
in Canada (e.g., Germany)
Frequency in setting Highest International Price Comparison test at introduction
16
14
12
10
8
6
4
2
0
France Germany Italy Sweden Switzerland UK USA
2008 0 2 0 1 0 2 3
2009 0 7 0 1 1 0 3
2010 0 6 0 0 0 0 4
2011 0 5 1 1 0 0 15
18
19. Regulatory Statistics
High level of compliance - On average, 93-95% overall compliance
2011 2010
New Drug Products 109 68
Introduced
Number of 69 87
Investigations
Between 2000 and 2009, average of 86 new patented drug
products/year
Of the 109 new drug products introduced in 2011:
79% within Guidelines
13% under investigation
8% outside of Guidelines but do not trigger an investigation
19